Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2012

View Archived Issues

New B-raf inhibitors presented by Array BioPharma and Genentech

Ablynx and Merck & Co. enter collaboration for Nanobody candidates

Intravenous dosing of GSK-322 investigated in healthy subjects

FDA approves extended-release liquid methylphenidate for ADHD

Phase III Abraxane trial meets primary endpoint

Astex begins phase II trial of SGI-110 in platinum-resistant recurrent ovarian cancer

PolyMedix presents new antimicrobials against biowarfare pathogens

Ipragliflozin has beneficial effects in Japanese patients with type 2 diabetes

Eravacycline compared to ertapenem in patients with intra-abdominal infections

Spanish researchers disclose new immunogenic compositions

Sanofi patents new 11-beta-HSD1 inhibitors

Merck Serono creates spin-off company to focus on neurodegenerative diseases

Ipsen provides update on hemophilia product agreement with Inspiration Biopharmaceuticals

Thrombolytic Science International begins phase I study of TS-01

Mallinckrodt completes acquisition

Athersys updates on MultiStem adult stem cell phase II study

Curis begins phase I trial of oral formulation of CUDC-101 in solid tumors

First data on once-weekly DPP IV inhibitor MK-3102 reported

Development and commercialization agreement reached for velusetrag for gastroparesis

Servier and EOS conclude collaboration and license agreement for E-3810

CBL-0102 receives U.S. orphan drug designation for hepatocellular carcinoma

Sanofi and Bristol-Myers Squibb restructure alliance

Omeros completes enrollment in second phase III OMS-302 trial

Phase Ib trial of RG-3039 commences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...